Because it slows gastric emptying, it may worsen gastrointestinal conditions
Animal studies demonstrated that exenatide reduced nicotine self-administration, nicotine-related reward behaviors, and dopamine release in the nucleus accumbens
However, coverage decisions ultimately depend on individual insurance plans and their formulary
Zepbound users lost up to 22.5% of body weight in clinical trials, while Ozempic users lost an average of about 14.9% Zepbound works on two receptors (GIP and GLP-1), giving it stronger effects on weight and blood sugar Both medications share similar side effects, mostly stomach-related symptoms Cost and insurance coverage vary widely, making accessibility a major factor in choosing between them Long-term use is required for both drugs to maintain results Choosing between Zepbound and Ozempic is a decision millions of people face when starting their weight loss journey
And that's the problem
Those seeking stronger and more sustained results are usually better suited to higher-dose weekly semaglutide injections or the dual GLP-1/GIP therapy tirzepatide, which has shown up to 20% weight loss in clinical trials
